The UK National Institute for Health and Care Excellence authorised GlaxoSmithKline's lupus drug Benlysta for limited use after rejecting the drug on the grounds of cost-effectiveness, as reported CNBC Tuesday.
NICE said the therapy will be made available under a managed access scheme between GlaxoSmithKline and the NHS.
Under the scheme, NICE will collect data on the benefits of the therapy and conduct a review after three years.
GlaxoSmithKline provided an undisclosed discount on the drug as part of its approval.
To read more NewsPoints articles, click here.